Recent studies of bulk microglia have provided insights into the role of this immune cell type in central nervous system development, homeostasis and dysfunction.
Overall, human microglia appear to exist in different functional states with varying levels of involvement in different brain pathologies.
Introduction
Our understanding of microglia has evolved rapidly with respect to their ontology, role in developmental and physiological plasticity, and involvement in pathophysiology 1, 2 . Historically, morphological studies using tissue sections 3 led to the notion of a linear continuum of cell states from a homeostatic state with a ramified morphology to an activated state with globular morphology. Recent transcriptome-wide studies of bulk ex vivo human microglia have consistently suggested that microglia change with age and have profiles enriched for disease genes [4] [5] [6] . Further, we observed that one microglial transcriptional program contributes to the accumulation of tau pathology while two others may relate to β-amyloid pathology 7 . However, these analyses used cortical-level data, and the need for greater resolution led us to characterize heterogeneity of human microglia at the single-cell level.
Genetic studies have highlighted a prominent role for microglia in susceptibility to different neurodegenerative diseases, particularly Alzheimer's disease (AD) and multiple sclerosis (MS) 6 , 8 . These syndromic diseases are heterogeneous at the clinical and pathologic level; for example, in a selection of over 1000 older individuals, more than 230 unique combinations of neuropathologic features were observed 9 . These concurrent pathologic processes create a diversity of contexts to which microglia respond, suggesting there may be large inter-individual variation in microglial states layered onto topological and functional variation of homeostatic microglia. This diversity of states makes targeting microglia in disease challenging: one has to carefully map which microglial subset to modulate and in which direction the immunomodulation must be applied.
To address this diversity, we profiled 15,910 cells isolated from the cerebral cortices of 7 aged and 8 young and middle-aged adults. Within the microglial cells (>97% of the cells), our data identified substantial heterogeneity in cell states, yielding an initial catalog of human microglial subpopulations. Compared to previous reports on mouse microglia 10 , 11 , the human brain seems to harbor a more nuanced impact of different disease processes that suggest an element of specialization of microglial cell states to different pathologic contexts.
Results

Nature and distribution of human single cell transcriptomic data
We elected to include a variety of adult human subjects to ensure that we captured a reasonable diversity of cortical microglia. Supplementary data 1 outlines the demographic characteristics and provenance of each of the profiled samples. In short, we processed 7 fresh autopsy samples from the dorsolateral prefrontal cortex, as well as 2 fresh samples of hippocampus and 6 samples of temporal neocortex from epilepsy surgeries. All samples were processed in the same manner, as previously described 6 , to extract live microglia: we sorted all CD45+/CD11b+/7AAD-cells from the autopsy samples ( Figure 1a) . In addition, since we observed the presence of rare CD45+/CD11b-events in the surgical biopsy samples, these were also included in the sequencing effort to comprehensively capture all viable immune cells in the CNS. The purified cell suspension from each processed sample was profiled using the dropletbased Chromium platform from 10x Genomics (Methods).
A rigorous pre-processing pipeline (Methods) expressed (1) C1QA, a microglial marker, at very low levels and (2) high levels of monocyte specific genes, such as FCN1, VCAN, and LYZ (Supplementary figure 2a) , suggesting these two clusters may represent monocytes or monocyte-derived cells. By contrast, the remaining 14 clusters express high levels of microglia-specific genes, such as C1QA, C1QB, C1QC and GPR34 (Supplementary figure 2b) ; we therefore deem these 14 clusters to be distinct clusters of microglial cell states.
Visualization of all the profiled cells in a t-SNE projection (Figure 2b) shows that the non-microglial clusters (13_1, 13_2, 15_1, 15_2, 12_1, 12_2, 12_3, 12_4 and 16) segregate from the microglial clusters. We assessed inter-cluster relatedness using a random forest-based machine learning approach to characterize how well individual cells could be unambiguously classified to each cluster 14 (see Methods section). We generated a "constellation diagram" 15 rather, independent microglial clusters appear to share similarities with cluster 1 but less so with each other. Although RNA-seq data alone is not sufficient to distinguish cell subtypes from cell states, the degree of similarity between clusters 1, 2, and 3 suggests that they might be different states of the same underlying cell subtype, whereas the remaining clusters might represent more specialized subtypes of microglia. Finally, there are no ambiguous cells between any of the non-microglial and microglial clusters, highlighting the clear difference between microglia and other cell classes.
We then assessed the extent of inter-individual heterogeneity in our data (Supplementary figure 3) . First, cluster 1 and 2 are well-represented in most individuals (Figure 3a) . We therefore propose that cluster 1 may represent "homeostatic microglia" which fulfill routine tasks necessary for cortical function. Second, there is inter-individual variability in the frequency of other microglial clusters, and a subset of clusters (9_1,9_2,14_1,14_2) are present in only two older individuals (95 and 97 years old) or a single subject with epilepsy (cluster 11) (Figure 3b) . Further, one subject, "Epilepsy 1", has a different cluster frequency pattern from all other subjects ( Figure   3a ): clusters 1 and 2 are relatively small and the majority of microglia are distributed across 7 other clusters. For this subject alone, the tissue sample was taken from cortex that was monitored using subdural electrodes placed for intracranial electroencephalogram monitoring for nine days prior to the resection. The resulting distribution of microglia away from cluster 1 could thus represent a relatively nonspecific reaction away from homeostasis, caused by the presence of a foreign object.
Interestingly, clusters 9_1, 9_2, 14_1 and 14_2 were not induced in this sample, suggesting that they may not represent a non-specific reactive phenotype but might rather be an age-related state.
Annotating the clusters of human microglia 
Discrete microglial subsets are enriched for MS and AD genes
Given that we have too few subjects to directly evaluate the association of microglial clusters to diseases and human traits, we performed enrichment analyses (Methods) to identify clusters that may be implicated in disease. We used the DOSE Bioconductor (1) the molecularly specific measures of β-amyloid and PHF-tau tangle accumulation, (2) the slope of cognitive decline before death and (3) a measure of resilience to cognitive decline ("residual cognition") 22 , 23 . We find that clusters 14_1 and 14_2 (which contain genes related to the interferon response) are enriched for all of the investigated traits, while cluster 4 only showed an enrichment for Alzheimer's dementia and cognitive decline but not with the histopathological hallmarks of the disease (Figure 7b ).
We also evaluated modules of co-expressed genes defined in the aging human frontal cortex 21 that we had previously described as being enriched in microglial genes 7 .
These five modules include m116, the cortical module most enriched for microglial genes, and m5, which is associated with both accumulation of tau pathology and the number of morphologically activated microglia in cortical tissue 24 . Gene-set enrichment analysis (Supplementary figure 10, Supplementary data 8) shows that m116 is enriched in almost all microglial clusters while m5 is present in a subset of cell clusters. infiltrating cells). Second, multiple clusters contain disease-related genes. Thus, the role of microglia in human disease is likely to be more nuanced than what has been described in the mouse to date, but cluster 4 stands out amongst the other clusters as it emerges as disease-related from multiple different analyses. Finally, we find that several clusters which are enriched in interferon response genes are only seen in two older subjects and another (cluster 11) is seen only in one epilepsy subject, suggesting that there may be additional microglial states to discover in other human samples.
Our study has certain limitations that result from having profiled samples from a small number of individuals, given the difficulty in obtaining these samples and the use of a multi-step purification pipeline 6 to isolate live microglia from human brain tissue.
First, there may have been a survival bias among microglial subpopulations that are successfully profiled. Further, our sample preparation process results in the loss of potentially important topological information. Also, we have only sampled three cortical regions, and thus profiling a larger number of brain regions and subjects is necessary to improve our reference atlas. Finally, all of the disease analyses reported here are indirect, relying on enrichment analyses, and they will need to be confirmed by direct analysis as larger sample sizes become available.
Overall, this Resource opens several avenues of investigation: (1) the exploration of functions conducted by the human homeostatic microglial subtype that we have now defined molecularly, (2) the generation of more complete transcriptomes, epigenomes, and proteomes to elucidate the function of each cluster now that we have markers with which to purify them, (3) enhanced in silico analyses of genetic, or tissue-level transcriptomic and epigenomic data to assess which microglial subtypes are involved in traits of interest, and (4) the identification of the specific subset of microglia to prioritize in target validation and clinical development efforts that will lead to therapies that modulate microglial function in neurodegenerative diseases.
Data availability
The single cell based transcriptomic atlas of human microglia presented here is available in the form of a searchable platform at https://vmenon.shinyapps.io/microglia. The raw data files are available through Synapse (https://www.synapse.org/#!Synapse:syn3219045). . Autopsy samples originated from the DLPFC of deceased aged individuals with various pathologies, while surgical biopsy samples were from the temporal neocortex and hippocampus of young and middle-aged individuals undergoing temporal lobectomy surgery for intractable epilepsy. Brain myeloid cells were sorted based on their CD11b and CD45 expression in autopsy samples. In surgical samples, a CD45 single positive population was observed and was included in the purified sample. Each single cell suspension preparation of sorted brain myeloid cells was loaded onto one lane of the Chromium system (10x Genomics) and the resulting library was sequenced on the HiSeq4000 platform (Illumina). b-c Quality control of the scRNAseq dataset. The box plots represent the median (middle line), 25%, and 75% percentiles. Whiskers extend to the most extreme cell no more than 1.5 times the interquartile range, and all cells more extreme than the whiskers are represented as circles. Abbreviations: AD, Alzheimer's disease; AF647 (AlexaFluor647) and AF488 (AlexaFluor488), two different fluorochromes; DLPFC, dorsolateral prefrontal cortex; FACS, fluorescence activated cell sorting; FTD, fronto-temporal dementia; PD, Parkinson's disease; scRNAseq, single cell RNA sequencing; UMI, unique molecular identifier. 
Figure 3. Cluster distribution within donors and provenance of clusters. (a)
Distribution of the different cell clusters within donors. Each column represents a cluster, and each row represents a subject. The size of the circles corresponds to the number of cells present in each cluster for each subject. Cluster 1 is the largest cluster in most subjects. The data is normalized by rows. In each row, the different circles add up to 100%. Each subject is colored with a different color. (b) Representation of the subject-level origin of the cells in each cluster. The size of the circles corresponds to the number of cells assigned to each cluster in that subject. The data is normalized by columns so that the different circles add up to 100% in each column. Thus, for example, while most subjects have cells assigned to Cluster 6, the vast majority of cells assigned to Cluster 6 came from subject "Epilepsy 1. Supplementary figure 2. Identity of the myeloid clusters. a Violin plots representing the gene expression of genes that have been shown to be monocyte specific, when compared to microglia in a human study 4 . b Violin plots depicting the expression of genes that were found to be enriched in microglia when compared to monocytes in earlier mouse and human studies 4 The ROS and MAP cohorts at RADC. Five out of seven autopsy specimens used in this study originated from two prospective studies of aging: the Religious Orders Study (ROS) 1 and the Memory and Aging Project (MAP) 2 . Participants to enter these prospective studies have to be at least 53 (ROS) or 55 (MAP) years old and nondemented at the time of enrollment and sign an Anatomical Gift Act agreeing to donate their brain and spinal cord at the time of death. Each subject undergoes annual neuropsychologic evaluations while alive and a structured, quantitative neuropathologic examination at autopsy. Brain specimens were distributed for this project from autopsies taking place Sunday morning to Thursday. Only autopsies for which the post mortem delay was less than 12 hours were included in this study.
Shipping of brain specimens. After weighing, the tissue was placed in ice-cold transportation medium (Hibernate-A medium (Gibco, A1247501) containing 1% B27 serum-free supplement (Gibco, 17504044) and 1% GlutaMax (Gibco, 35050061)) and shipped overnight at 4°C with priority shipping.
Microglia isolation and sorting. The isolation of microglia was performed as described elsewhere 3 . Breifly, upon arrival of the autopsy sample, the cortex and the underlying white matter were dissected under a stereomicroscope. The epilepsy surgery samples were processed without dissection as in this case the cortical white and grey matter were not always distinguishable. All procedures were performed on ice. From the autopsy sample only microglia isolated from the grey matter were used in this study. The dissected tissue was placed in HBSS (Lonza, 10-508F) and weighed. Subsequently the tissue was homogenized in a 15 ml glass tissue grinder -0.5g at a time. The resulting homogenate was filtered through a 70 um filter and spun down with 300g for 10 minutes. The pellet was resuspended in 2 ml staining buffer (PBS (Lonza, ) containing 1% FBS) per 0.5g of initial tissue and incubated with anti-myelin magnetic beads (Miltenyi, 130-096-733) for 15 minutes according to the manufacturers specification. The homogenate was than washed once with staining buffer and the myelin was depleted using Miltenyi large separation columns. The cell suspension was spun down and incubated with anti-CD11b magnetic beads (Miltenyi, 130-049-601) for 15 minutes. Following a wash with staining buffer the CD11b+ cells were isolated on a Miltenyi MS column while the CD11-fraction was cryopreserved using FBS containing 10% DMSO. The CD11b positive fraction was than incubated with anti-CD11b AlexaFluor488 (BioLegend, 301318) and anti-CD45 AlexaFluor647 (BioLegend, 304018) antibodies as well as 7AAD (BD Pharmingen, 559925) for 20 minutes on ice. Subsequently the cell suspension is washed twice with staining buffer, filtered through a 70 um filter and the CD11b+/CD45+/7AAD-cells (Supplementary figure 1b) were sorted on a BD FACS Aria II sorter. Cells were sorted in A1 well of a 96 well PCR plate (Eppendorf, 951020401) containing 100 ul of PBS buffer and submitted to single cell library construction.
10x Genomics Chromium single cell 3' library construction. Viability was assessed by trypan blue exclusion assay and cell density was adjusted to 175 cells per µl. 7,000 cells were then loaded on a single channel on the 10x Chromium chip from each sample. The 10x Genomics Chromium technology enables 3' digital gene expression profiling of thousands of cells from a single sample by separately indexing each cells transcriptome. First, thousands of cells will be partitioned into nanoliter-scale Gel BeadIn-EMulsions (GEMs). Within one GEM all generated cDNA share a common 10x barcode. Libraries are generated and sequenced from the cDNA and the 10x barcodes are used to associate individual reads back to the individual partitions. To achieve single cell resolution, the cells are delivered at a limiting dilution. Upon dissolution of the Single Cell 3' Gel Bead in a GEM, primers containing (i) an Illumina R1 sequence (read 1 sequencing primer), (ii) a 16 nt 10x Barcode, (iii) a 10 nt Unique Molecular Identifier (UMI), and (iv) a poly-dT primer sequence are released and mixed with cell lysate and Master Mix. Incubation of the GEMs then produces barcoded, full-length cDNA from poly-adenylated mRNA. After incubation, the GEMs are broken and the pooled fractions are recovered. Full-length, barcoded cDNA is then amplified by PCR to generate sufficient mass for library construction. Enzymatic fragmentation and size selection are used to optimize the cDNA amplicon size prior to library construction. R1 (read 1 primer sequence) are added to the molecules during GEM incubation. P5, P7, a sample index, and R2 (read 2 primer sequence) are added during library construction via end repair, A-tailing, adaptor ligation, and PCR. The final libraries contain the P5 and P7 primers used in Illumina bridge amplification. The described protocol produces Illumina-ready sequencing libraries. A Single Cell 3' Library comprises standard Illumina paired-end constructs which begin and end with P5 and P7. The Single Cell 3' 16 bp 10x Barcode and 10 bp UMI are encoded in Read 1, while Read 2 is used to sequence the cDNA fragment. Sample index sequences are incorporated as the i7 index read. Read 1 and Read 2 are standard Illumina sequencing primer sites used in paired-end sequencing. Sequencing the generated library produces a standard Illumina BCL data output folder. The BCL data will include the paired-end Read 1 (containing the 16 bp 10x Barcode and 10 bp UMI) and Read 2 and the sample index in the i7 index read.
Batch structure and sequencing
The fresh autopsy and surgical resection samples were processed for microglia isolation, library construction and sequencing as they were obtained. Accordingly each sample constitute one batch for all three procedures. All sequencing was performed on an Illumina HiSeq4000 machine. For specifics regarding the generated reads see Supplementary data 2.
Computational methods
Barcoded reads were demultiplexed and aligned to the GRCh38 genome with Ensemble transcriptome annotation (downloaded June 2017, GRCh38.85) using CellRanger with default parameters. Only cells with >1000 Unique Molecular Identifiers (UMIs) were kept for clustering and downstream analysis. Putative cell types were identified using an iterative clustering approach; after regressing out batch and total UMI number, all genes with variance greater than the mean were used to cluster cells with the PCA-Louvain clustering approach, as implemented in the Seurat R package 4 . After clustering, cluster robustness was assessed by training a classifier on half the cells and predicting the cluster membership of the remaining half. Any clusters that showed a minimum less than 50% accurate prediction over 20 iterations were merged. Each cluster was then iteratively subclustered using the same procedure until no further robust clusters were found. After clustering, differential genes were identified over all pairs of clusters using the edgeR package 5 . Constellation diagrams showing the relationship among different clusters were generated using a cross-validation machine learning approach 6 . For each pair of clusters, cells were classified using five-fold cross-validation using a random forest classifier (trained on 80% of the cells). This process was repeated 10 times, resulting in a membership score for each cell belonging to one or the other cluster in the pair. Cells that were not unambiguously classified (10 times out of 10) to the same cluster were called "intermediate" cells. For the constellation diagram, the edges between any two clusters represent the percentage of total cells (from the pair of clusters) that were called "intermediate", and the size of the nodes represents the total (core+intermediate) cells originally assigned to that cluster. For dotplot representations, expression values for a given gene were z-scored over all the cells belonging to all the clusters visualized, and then per-cluster means of the zscored values were calculated and plotted using the color scheme shown in each figure. Sizes of the circles represent the number of cells in the cluster in which the gene was detected (TPM>0). For all gene-based association tests, we first obtained lists of cluster-specific genes; for each cluster, this comprised all genes that showed statistically significant up-regulation in comparison to at least one cluster, with the constraint that the gene did not show significant down-regulation with respect to any other cluster. Using these cluster-specific gene lists, we performed gene ontology analysis using the topGO R package 7 with standard parameters and Benjamini-Hochberg procedure to control the FDR rate. Disease ontology analyses were performed using the DOSE R package 8 , also with standard parameters and Benjamini-Hochberg procedure. To assess enrichment cluster-specific signatures in previously-reported microglial modules derived from bulk data 9 , 10 . Gene-set enrichment analyses were performed with Mann-Whitney test to assess whether the module-specific genes showed a different distribution of minimum 
